EDSA News and Press, Edesa Biotech Inc. From 06/25/21

As the standard first-line treatment for osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, and general pain reduction, naproxen and other NSAIDs are effective, but can induce ulceration and bleeding of the digestive tract, with much higher incidence in patients, as noted by An...

TORONTO, ON / ACCESSWIRE / June 23, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced the appointment of a key member to its management team to support the company's expanding manufacturin...

CAI International (CAI) +46% on merger deal with Mitsubishi HC Capital.Sykes Enterprises (SYKE) +30% on being acquired by Sitel group for $54.0 per share.AnPac Bio-Medical Science (ANPC) +22% after securing first disease treatment patent in U.S.Geron Corporation (GERN) +20% ...

Edesa Biotech (EDSA) jumps 10% premarket following a report that an independent Data and Safety Monitoring Board ((DSMB)) has completed an interim review of the company's COVID-19 drug candidate, and has recommended the study to continue as planned. An interim review of the first pa...

TORONTO, ON / ACCESSWIRE / June 18, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported that an independent Data and Safety Monitoring Board (DSMB) has completed an interim review of the comp...

TORONTO, ON / ACCESSWIRE / June 8, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, announced today that the company's senior management are scheduled to attend the 2021 BIO Digital Conference being held...

Edesa Biotech (EDSA) announces that the company's drug candidate EB01 has met a key interim study parameter in a mid-stage Allergic Contact Dermatitis ((ACD)) trial.Shares up nearly 4% premarket.The company has now passed the initial inflection point of its Phase2b study and wi...

TORONTO, ON / ACCESSWIRE / June 3, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today announced that the company's drug candidate EB01 has met a key interim study parameter. The company has now passe...

TORONTO, ON / ACCESSWIRE / May 28, 2021 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company, announced today that Dr. Par Nijhawan, Chief Executive Officer, is scheduled to participate in a virtual event organized by the Ontario Bioscience Innovation Organization....

Edesa Biotech (EDSA): FQ2 GAAP EPS of -$0.19 beats by $0.10.Cash and cash equivalents of $10.97MPress Release For further details see: Edesa Biotech EPS beats by $0.10